Home › Companies › MOONLAKE IMMUNOTHERAPEUTICS › 2025-2026
Compiled from SEC Form N-PX filings and MOONLAKE IMMUNOTHERAPEUTICS’s Form 8-K, filed 2026-06-09 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore MOONLAKE IMMUNOTHERAPEUTICS in the interactive database Compare manager voting policies
These tallies are MOONLAKE IMMUNOTHERAPEUTICS’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-09 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Proposal 2: Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor | 61,831,463 | 17,522 | 23,521 | -- | 0 | Majority: yes |
| Proposal 3: Advisory Vote on Executive Compensation | 50,365,168 | 731,158 | 15,038 | -- | 10,761,142 | Majority: yes |
| Proposal 4: Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan | 50,599,032 | 498,186 | 14,146 | -- | 10,761,142 | Majority: yes |
Source: MOONLAKE IMMUNOTHERAPEUTICS, Form 8-K, filed with the SEC on 2026-06-09 — read the filing on EDGAR.
Each item below shows how the 124 asset managers that disclosed a MOONLAKE IMMUNOTHERAPEUTICS vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of MOONLAKE IMMUNOTHERAPEUTICS’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation”): 50,365,168 for, 731,158 against, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 73,615,396 outstanding shares: 68% for, 1.0% against (69% of the company cast a for/against vote).
The 123 asset managers below cast 99% of the shares they voted on this item FOR (49,774,333 for, 723,245 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BVF INC/IL | 16,001,284 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 6,408,863 | 0 | 0 | 0 | For |
| Janus Henderson | 6,184,466 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 3,111,387 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,816,912 | 0 | 0 | 0 | For |
| Logos Global Management LP | 1,821,262 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 1,811,082 | 0 | 0 | 0 | For |
| Two Sigma | 1,029,486 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 1,000,000 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 1,000,000 | 0 | 0 | 0 | For |
| BlackRock | 910,702 | 8,921 | 0 | 0 | For |
| Citadel | 903,150 | 0 | 0 | 0 | For |
| DE Shaw | 720,083 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 661,770 | 0 | 0 | 0 | For |
| Point72 | 653,057 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 415,973 | 0 | 0 | 0 | For |
| Holocene Advisors, LP | 402,429 | 0 | 0 | 0 | For |
| Fidelity | 375,398 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 340,426 | 0 | 0 | Against |
| Voleon Capital Management LP | 315,684 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 276,224 | 0 | 0 | 0 | For |
| Boxer Capital Management, LLC | 266,927 | 0 | 0 | 0 | For |
| Renaissance | 215,740 | 0 | 0 | 0 | For |
| HighVista Strategies LLC | 193,955 | 0 | 0 | 0 | For |
| ACUTA CAPITAL PARTNERS, LLC | 192,364 | 0 | 0 | 0 | For |
Showing the 25 largest of 123 asset managers. See all 123 in the interactive database.
99.0% Majority: yes · of votes cast
MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Proposal 4: Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan”): 50,599,032 for, 498,186 against, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 73,615,396 outstanding shares: 69% for, 0.7% against (69% of the company cast a for/against vote).
The 19 asset managers below cast 100% of the shares they voted on this item FOR (2,359,035 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 1,222,173 | 0 | 0 | 0 | For |
| BlackRock | 286,416 | 0 | 0 | 0 | For |
| Fidelity | 231,840 | 0 | 0 | 0 | For |
| Jackson National | 111,754 | 0 | 0 | 0 | For |
| Vanguard | 95,233 | 0 | 0 | 0 | For |
| Invesco | 94,234 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 80,000 | 0 | 0 | 0 | For |
| Victory Capital | 64,317 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 58,395 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 24,419 | 0 | 0 | 0 | For |
| John Hancock | 22,585 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 17,562 | 0 | 0 | 0 | For |
| Vident Advisory, LLC | 17,361 | 0 | 0 | 0 | For |
| Equitable | 17,151 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 10,515 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,000 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 826 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 244 | 0 | 0 | 0 | For |
| E Trade Trust | 10 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
100% fund support · no official result
The 18 asset managers below cast 100% of the shares they voted on this item FOR (2,250,906 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 1,222,173 | 0 | 0 | 0 | For |
| BlackRock | 286,416 | 0 | 0 | 0 | For |
| Fidelity | 231,840 | 0 | 0 | 0 | For |
| Jackson National | 111,754 | 0 | 0 | 0 | For |
| Vanguard | 94,980 | 0 | 253 | 0 | For |
| Invesco | 94,234 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 80,000 | 0 | Abstain |
| Victory Capital | 64,317 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 58,395 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 24,419 | 0 | 0 | 0 | For |
| John Hancock | 22,585 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 17,562 | 0 | 0 | 0 | For |
| Equitable | 17,151 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 0 | 0 | 10,515 | 0 | Abstain |
| Blackstone Alternative Investment Funds | 4,000 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 826 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 244 | 0 | 0 | 0 | For |
| E Trade Trust | 10 | 0 | 0 | 0 | For |
99.9% Majority: yes · of votes cast
MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Proposal 2: Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor”): 61,831,463 for, 17,522 against, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 73,615,396 outstanding shares: 84% for, 0.1% against (84% of the company cast a for/against vote).
The 18 asset managers below cast 100% of the shares they voted on this item FOR (2,341,674 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 1,222,173 | 0 | 0 | 0 | For |
| BlackRock | 286,416 | 0 | 0 | 0 | For |
| Fidelity | 231,840 | 0 | 0 | 0 | For |
| Jackson National | 111,754 | 0 | 0 | 0 | For |
| Vanguard | 95,233 | 0 | 0 | 0 | For |
| Invesco | 94,234 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 80,000 | 0 | 0 | 0 | For |
| Victory Capital | 64,317 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 58,395 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 24,419 | 0 | 0 | 0 | For |
| John Hancock | 22,585 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 17,562 | 0 | 0 | 0 | For |
| Equitable | 17,151 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 10,515 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,000 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 826 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 244 | 0 | 0 | 0 | For |
| E Trade Trust | 10 | 0 | 0 | 0 | For |
Ranked by the number of MOONLAKE IMMUNOTHERAPEUTICS shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 73,615,396 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BVF INC/IL | 21.74% |
| 2 | Deep Track Capital, LP | 8.71% |
| 3 | Janus Henderson | 8.40% |
| 4 | Cormorant Asset Management, LP | 4.23% |
| 5 | T. Rowe Price | 3.83% |
| 6 | Logos Global Management LP | 2.47% |
| 7 | MPM BioImpact LLC | 2.46% |
| 8 | Two Sigma | 1.40% |
| 9 | GREAT POINT PARTNERS LLC | 1.36% |
| 10 | Vivo Capital, LLC | 1.36% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BVF PARTNERS L P/IL | 21.74% | 13D |
| Certain funds managed by BVF Partners L.P. | 21.74% | DEF14A |
| Deep Track Capital, LP | 10.87% | 13G |
| Entities affiliated with Deep Track Capital, LP | 6.26% | DEF14A |
| Entities affiliated with Cormorant Asset Management, LP | 5.92% | DEF14A |
| Dr. Jorge Santos da Silva | 4.18% | DEF14A |
| Dr. Kristian Reich | 4.14% | DEF14A |
| D.E. Shaw | 3.25% | 13F |
| Citadel Advisors | 2.83% | 13F |
| Point72 | 1.86% | 13F |
Percentages above are of 73,615,396 shares outstanding, as reported by MOONLAKE IMMUNOTHERAPEUTICS on its Form 10-Q dated 2026-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MOONLAKE IMMUNOTHERAPEUTICS’s 10-Q dated 2026-05-01. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At MOONLAKE IMMUNOTHERAPEUTICS's shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 124 asset managers reported how they voted in their SEC Form N-PX filings, covering 315 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval of, on a non-binding, advisory basis, the compensation of the Company's named… — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: MOONLAKE IMMUNOTHERAPEUTICS's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-09.
MOONLAKE IMMUNOTHERAPEUTICS proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).